Eisai Co., Ltd. (ESAIY) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - Specialty & Generic secteur d'activité. Le siège social de l'entreprise est situé à Tokyo, Japan. Le PDG actuel est Haruo Naito.
ESAIY a date d'introduction en bourse 2023-02-02, 11,067 employés à temps plein, cotée sur le Other OTC, une capitalisation boursière de $9.03B.
Eisai Co., Ltd. is a Tokyo-based pharmaceutical company founded in 1941 that engages in the research, development, manufacture, and commercialization of prescription medications across multiple therapeutic areas. The company's product portfolio includes Dayvigo for insomnia, Lenvima for various cancers including thyroid and renal cell carcinoma, Aricept for Alzheimer's disease, Halaven for breast cancer, and Fycompa for epilepsy, among other medications addressing neurology, oncology, gastroenterology, and other specialties. Eisai maintains a strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin, an antibody drug conjugate. The company operates globally with a strong presence in Japan and serves both domestic and international markets through its research and manufacturing operations.
